Dr. Elizabeth Heritage Cull, MD

Dr. Cull practices at Prisma Health Greenville Memorial Hospital in Greenville, South Carolina, part of Prisma Health.

Dr. Cull's NPI, 1356674527, was assigned on September 6, 2009. Dr. Cull holds South Carolina license 37970.

Dr. Cull's primary practice is Prisma Health Greenville Memorial Hospital, at 701 Grove Road, Greenville, SC 29605 in Greenville County. The practice phone is (864) 455-7000.

Dr. Cull's primary practice is Prisma Health Greenville Memorial Hospital in Greenville, South Carolina, part of Prisma Health. Dr. Cull is also affiliated with Prisma Health Patewood Hospital. The medical group on file is Prisma Health Medical Group. Dmand AI also links Dr. Cull to 3 more hospitals, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cull practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Cull's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Cull's licenses on file in 2 states: South Carolina and Illinois.

CMS data shows 1,697 Medicare services from Dr. Cull across 10 procedure codes in 2024, for 339 Medicare patients. Medicare paid $72,780 for them.

CMS counts 339 Medicare patients who saw Dr. Cull in 2024. The largest group is 75 to 84, with 144 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cull's median patient age at 66, with 53% women.

In 2024, Dr. Cull wrote 1,693 Medicare Part D claims for 207 patients. 68% of them were for generic drugs. CMS names the drug for 1,426 of them, across 42 drugs with 11 or more claims each, at $6,910,403 in total drug cost. In 2023, CMS named 973 claims across 38 drugs.

Dr. Cull accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cull as offering telehealth.

Dmand AI links 15 papers to Dr. Cull, published from 2012 to 2024. 2021 was the busiest year, with 5. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized and Antineoplastic Agents. Dr. Cull has published most often in Leuk Lymphoma. Dr. Cull's most frequent co-authors are Jessica Kaplan Altman, MD, Tara L. Lin, MD and Alice Scott Mims, MD.

Dmand AI links Dr. Cull to 10 clinical trials, 4 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute and Lymphoma, Large B-Cell, Diffuse. Aptose Biosciences Inc. sponsors the most, 2.

CMS Open Payments shows 121 general payments to Dr. Cull from 39 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 71% of the total. Celgene Corporation paid the most, $22,904.